Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-23
2000-06-13
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 530300, 530317, 530326, 530327, A01N 3718, A61K 3800, A61K 3812, A61K 3804
Patent
active
060750049
ABSTRACT:
Peptide compositions which inhibit the binding of one protein to another protein, and corresponding methods of use are disclosed. These peptide compositions include at least one peptide which binds to one protein, and at least one peptide which binds to the other protein. In the preferred embodiment, the peptide composition is composed of a combination of cyclic ICAM-1-based and LFA-1-based peptides which inhibit the binding of LFA-1 to ICAM-1. Such LFA-1/ICAM-1-based peptide compositions can be used to treat disease states such as rejection of transplanted organs, allergies, and autoimmune diseases.
REFERENCES:
patent: 5340800 (1994-08-01), Liu et al.
patent: 5437958 (1995-08-01), Gallatin et al.
patent: 5470953 (1995-11-01), Gallatin et al.
Webster's II New Riverside University Dictionary, The Riverside Publishing Co., Boston, p 871, 1994.
Chirathaworn et al.; Cross-linking of ICAM-1 on T cells induces transient tyrosine phosphorylation and inactivation of cdc2 kinase; The Journal of Immunology; 155:5479-5482 (1995).
Dustin et al.; T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1; Nature; 341:619-624 (1989).
Butler et al.; Modulation of T cell morphology and induction of homotypic adhesion by a protein tyrosine kinase inhibitor; Cellular Immun., 162:1-10 (1995).
Pierschbacher et al.; Synthetic peptide with cell attachment activity of fibronectin; Proc. Natl. Acad. Sci. USA; 80:1224-1227 (1983).
Pierschbacher et al.; Call attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule; Nature, Macmillan Journals Ltd., 1984.
Randi et al.; I domain of .beta..sub.2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1; J. Biol. Chem., 269(17):12395-12396 (1994).
Nortamo et al.; A peptide from ICAM-2 binds to the leukocyte integrin CD11a/CD18 and inhibits endothelial cell adhesion; J. Biol. Chem., 268(23):17513-17518 (1993).
Ross et al.; Inhibition of molt-4-endothelial adherence by synthetic peptides from the sequence of ICAM-1; J. Biol. Chem., 267(12):8537-8543 (1992).
Masumoto et al.; Multiple activation states of VLA-4; J. Biol. Chem.; 268(1):228-234 (1993).
Stanley et al.; Integrin LFA-1 .alpha. subunit contains an ICAM-1 binding site in domains V and VI; EMBO J.; 13(8):1790-1798 (1994).
Current Protocols in Immunology, vol. 1, Sections. 4.4.1-4.4.12 (1992), Green Publishing Associates, Inc. and John Wiley & sons, Inc.
Flory, Phase changes in proteins and polypeptides; Mellon Institute, Pittsburg, PA (date unknown).
Merrifield; The chemical synthesis of peptides and proteins; Rockefeller University, New York, NY; Copyright 1971 by Beckman Instruments, Inc.
van Kooyk et al.; Activation ofLFA-1 through a Ca.sup.2+ -dependent epitope stimulates lymphocyte adhesion; J. Cell Biology; 112(2):345-354 (1991).
Welder et al.; Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1.sup.1 ; J. Immunology; 150(6):2203-2210 (1993).
Isobe et al.; Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1; Science; 255:1125-127 (1992).
Springer; Adhesion receptors of the immune system; Nature; 346:425-433(1990).
Tuomanen; Subversion of leikocyte adhesion systems by respiratory pathogens; ASM News ; 59(6):292-296 (1993).
Sherman-Gold; Companies pursue therapies based on complex cell adhesion molecules; Genetic Engineering News; 13(13):6 (1993).
Waldmann et al.; the use of monoclonalantibodies to achieve immunological tolerance; Immunology Today; 14(6):247-251 (1993).
Steinman; Autoimmune disease; Scientific American; 107-114 (1993).
Marrack et al.; How the immune system recognizes the body; Scientific American; 81-89 (1993).
Weissman et al.; How the immune system develops; Scientific American; 65-71 (1993).
Nossal; Life, death and the immune system; Scientific American; 53-62 (1993).
Nakakura et al.; Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion; Transplantation; 55(2):412-417 (1993).
Talento et al.; A single administration of LFA-1 antibody confers prolonged allograft survival; Transplantation; 55(2):418-422 (1993).
Ezzell; Antibody combo nixes graft rejection; Science News; vol. 14 (date unknown).
Merrifield; Automated synthesis of peptides; Science; 15:178-185 (1965).
Larson et al.; Primary structure of the leukocyte function-associated molecule-1 .alpha. subunit: anintegrin with an embedded domain defining a protein superfamily; J. Cell Biology; 108:703-712 (1989).
Landis et al.; A novel LFA-activation epitope maps to the I domain; J. Cell Biology; 120(6):1519-1527 (1993).
Li et al.; A leukocyte integrin binding peptide from intercellular adhesion molecule-2 stimulates T cell adhesion and natural killer cell activity; J. Biol. Chem.; 268(29):21474-21477 (1993).
The Adhesion Molecule Facts Book, Pigott & Power, Academic Press (San Diego), 1993, pp. 93-97, 74-78.
Hynes; Integrins: Versatility, Modulation and Signaling in Cell Adhesion; Cell; 69:11-25 (1992).
Benedict Stephen
Chan Marcia A.
Siahaan Teruna J.
Tibbetts Scott A.
Hutzell Paula K.
The University of Kansas
Ungar Susan
LandOfFree
Peptide compositions which induce immune tolerance and methods o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide compositions which induce immune tolerance and methods o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide compositions which induce immune tolerance and methods o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2068810